irinotecan has been researched along with 2,5-dimethylcelecoxib in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, CS; Chen, TC; Hofman, FM; Kardosh, A; Liu, YT; Petasis, NA; Pyrko, P; Schönthal, AH; Soriano, N; Uddin, J | 1 |
1 other study(ies) available for irinotecan and 2,5-dimethylcelecoxib
Article | Year |
---|---|
Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Celecoxib; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression Regulation; HCT116 Cells; Humans; Inhibitor of Apoptosis Proteins; Irinotecan; Male; Mice; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Proteins; Neuroblastoma; Promoter Regions, Genetic; Pyrazoles; Sulfonamides; Survivin; Transcription, Genetic; Transfection; Xenograft Model Antitumor Assays | 2006 |